WHO ICTRP trial
A study on the Combination of Gemcitabine, Cisplatin, Nab-Paclitaxel, and…
KCT0010102 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0010102 |
|---|---|
| Public title | A study on the Combination of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Tislelizumab in Treatment-Naïve Patients with Biliary Tract Cancer |
| Scientific title | A multicenter Phase 1b/2 Trial Investigating the Efficacy and Toxicity of the Combination of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Tislelizumab in Treatment-Naïve Patients with Unresectable, Locally Advanced, or Metastatic Biliary Tract Cancers (GemCiNT) |
| Primary sponsor | Bundang CHA General Hospital |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase1/Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : Phase 1b Tislelizumab : 200mg, IV, every 3 weeks, D1 Nab-paclitaxel : 50~100 mg/m2, IV, every 3 weeks, D1 and D8 (administering up to 16 cycles) Gemcitabine : 1000mg/m2, IV, every 3 weeks, Day1 and Day8 Cisplatin : 25 mg/m2, IV… |
| Registration date | Jan 3, 2025 |
| Target size | 61 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: